<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Etanercept biosimilar geçişi &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/etanercept-biosimilar-gecisi/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 18 Nov 2025 14:59:27 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Etanercept biosimilar geçişi &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Evaluating Etanercept Biosimilar Switching: Efficacy and Safety</title>
		<link>https://bioengineer.org/evaluating-etanercept-biosimilar-switching-efficacy-and-safety/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 18 Nov 2025 14:59:21 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Clinical evidence** * **Biosimilar switching:** Makalenin ana konusu]]></category>
		<category><![CDATA[Efficacy safety]]></category>
		<category><![CDATA[Etanercept biosimilar geçişi]]></category>
		<category><![CDATA[Etanercept biosimilars]]></category>
		<category><![CDATA[etkinlik ve güvenlik üzerine odaklanan bu içeriğe uygun 5 etiket: **Biosimilar switching]]></category>
		<category><![CDATA[Narrative review]]></category>
		<category><![CDATA[orijinal ilaçtan biosimilere geçişin değerlendiril]]></category>
		<guid isPermaLink="false">https://bioengineer.org/evaluating-etanercept-biosimilar-switching-efficacy-and-safety/</guid>

					<description><![CDATA[In recent years, the advent of biosimilars has revolutionized the landscape of therapeutic options available for chronic inflammatory conditions such as rheumatoid arthritis and psoriasis. Among these biosimilars, etanercept has emerged as a pivotal treatment option. Etanercept is a biologic agent that has been widely utilized since its initial approval, and its biosimilar versions are [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">298261</post-id>	</item>
	</channel>
</rss>
